AXSM - Axsome Therapeutics GAAP EPS of -$1.07 beats by $0.02 revenue of $16.8M misses by $0.26M
- Axsome Therapeutics press release ( NASDAQ: AXSM ): Q3 GAAP EPS of -$1.07 beats by $0.02 .
- Revenue of $16.8M misses by $0.26M .
- Cash and cash equivalents totaled $227.5 million at September 30, 2022, compared to $86.5 million at December 31, 2021. During the quarter, the Company utilized its existing at-the-market equity facility and received net proceeds of $175 million.
For further details see:
Axsome Therapeutics GAAP EPS of -$1.07 beats by $0.02, revenue of $16.8M misses by $0.26M